Company profile
InnoUp
Innovation makes us better
- Industry
- Biotechnology Research
- Employees
- 8
- Headquarters
- Noáin, Comunidad Foral de Navarra
- Founded
- 2015
- LinkedIn followers
- 1,687
- Office locations
- 1
InnoUp company summary
InnoUp is a company in the Biotechnology Research industry, headquartered in Noáin, Comunidad Foral de Navarra, founded in 2015. On LinkedIn the company has around 8 employees and 1,687 followers. Its listed specialties include nanomedicine, nanotechnology, dru encapsulation, food allergies, peanut allergy.
What technology does InnoUp use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About InnoUp
InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.
Specialties
Where is InnoUp located?
InnoUp lists 1 location.
Compare companies similar to InnoUp
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
InnoUp innoupfarma.com | Biotechnology Research | 8 | 2015 | Noáin, Comunidad Foral de Navarra |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about InnoUp
What does InnoUp do?
InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.
How many employees does InnoUp have?
InnoUp has around 8 employees on LinkedIn.
Where is InnoUp headquartered?
InnoUp is headquartered in Noáin, Comunidad Foral de Navarra.
When was InnoUp founded?
InnoUp was founded in 2015.
Build a lead list from companies like InnoUp
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.